RT Journal Article
SR Electronic
T1 Quantifying and Imaging NY-ESO-1/LAGE-1-Derived Epitopes on Tumor Cells Using High Affinity T Cell Receptors
JF The Journal of Immunology
JO J. Immunol.
FD American Association of Immunologists
SP 7308
OP 7316
DO 10.4049/jimmunol.176.12.7308
VO 176
IS 12
A1 Purbhoo, Marco A.
A1 Sutton, Deborah H.
A1 Brewer, Joanna E.
A1 Mullings, Rebecca E.
A1 Hill, Maxine E.
A1 Mahon, Tara M.
A1 Karbach, Julia
A1 Jäger, Elke
A1 Cameron, Brian J.
A1 Lissin, Nikolai
A1 Vyas, Paresh
A1 Chen, Ji-Li
A1 Cerundolo, Vincenzo
A1 Jakobsen, Bent K.
YR 2006
UL http://www.jimmunol.org/content/176/12/7308.abstract
AB Presentation of intracellular tumor-associated Ags (TAAs) in the context of HLA class I molecules offers unique cancer-specific cell surface markers for the identification and targeting of tumor cells. For most peptide Ags, the levels of and variations in cell surface presentation remain unknown, yet these parameters are of crucial importance when considering specific TAAs as targets for anticancer therapy. Here we use a soluble TCR with picomolar affinity for the HLA-A2-restricted 157–165 epitope of the NY-ESO-1 and LAGE-1 TAAs to investigate presentation of this immunodominant epitope on the surface of a variety of cancer cells. By single molecule fluorescence microscopy, we directly visualize HLA-peptide presentation for the first time, demonstrating that NY-ESO-1/LAGE-1-positive tumor cells present 10–50 NY-ESO-1/LAGE-1157–165 epitopes per cell.